Company profile
Stemtech Corporation
OTC: STEK · Healthcare · Drug Manufacturers - Specialty & Generic
#760 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
26DFH 28DQ 19GM 41SS 13
v0.1 · 65/100 weight · provisional
↑ growth stability, operating margin · ↓ workforce scale, Piotroski F
Methodology →Revenue TTM
$2.5M
Rev growth YoY (TTM)
-45.6%
Net income (FY)
-$4.0M
Employees
1
as of 2026-08-29
Market cap
$216.9k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.9M$2.9M2025
Net income-$4.0M-$4.0M2025
Operating income-$2.7M-$2.7M2025
Total assets$3.1M$3.1M2025
Liabilities$10.6M$10.6M2025
Equity-$7.0M-$7.0M2025
Revenue trend
FY2021 – FY2025 · USD
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Operating Segments100%
By geography
Latin America53%
Americas43%
Asia4%
The read
What is Stemtech Corporation’s revenue?
Stemtech Corporation booked $2.9M in FY2025 revenue, contracting 43% year over year — slower than 79% of Healthcare companies we track, at a -140.7% net margin.
Peers · Healthcare
Amexdrug Corporation69BRadient Technologies Inc.——SCWorx Corp.49DDental Patient Care America, Inc.73BUpstream Bio, Inc.44DMedical Supply International USA, Inc.——Neighbors
Collier →Key facts
CEOCharles S. Arnold
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersNaples, FL
ExchangeOTC: STEK
Employees1
IPO date2021-11-26
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.